Principal Financial Group Inc. Sells 3,743 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Principal Financial Group Inc. reduced its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 3.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 119,726 shares of the company's stock after selling 3,743 shares during the period. Principal Financial Group Inc. owned about 0.42% of Krystal Biotech worth $21,794,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Price T Rowe Associates Inc. MD raised its stake in Krystal Biotech by 54.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company's stock valued at $117,189,000 after purchasing an additional 231,255 shares during the period. Bank of New York Mellon Corp lifted its stake in Krystal Biotech by 115.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company's stock worth $35,583,000 after acquiring an additional 103,928 shares in the last quarter. Capital World Investors purchased a new stake in Krystal Biotech in the 1st quarter worth about $17,285,000. Public Sector Pension Investment Board acquired a new stake in Krystal Biotech during the 2nd quarter worth about $10,037,000. Finally, Scout Investments Inc. purchased a new position in Krystal Biotech during the 1st quarter valued at about $8,976,000. Institutional investors and hedge funds own 86.29% of the company's stock.

Krystal Biotech Stock Down 2.2 %

KRYS stock traded down $4.12 during midday trading on Thursday, hitting $180.10. 111,817 shares of the company traded hands, compared to its average volume of 328,296. The business has a 50 day simple moving average of $181.27 and a 200-day simple moving average of $181.38. Krystal Biotech, Inc. has a twelve month low of $96.73 and a twelve month high of $219.34. The stock has a market capitalization of $5.18 billion, a price-to-earnings ratio of 104.08 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.84 by $0.07. The firm had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business's quarterly revenue was up 879.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.67) EPS. Equities research analysts forecast that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently commented on KRYS shares. Chardan Capital raised their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a "buy" rating in a report on Monday, August 5th. HC Wainwright reaffirmed a "buy" rating and issued a $221.00 price target on shares of Krystal Biotech in a research note on Tuesday, November 5th. Stifel Nicolaus lifted their price objective on Krystal Biotech from $204.00 to $220.00 and gave the company a "buy" rating in a research report on Wednesday, September 11th. William Blair raised Krystal Biotech to a "strong-buy" rating in a research report on Friday, August 30th. Finally, Evercore ISI lifted their price target on Krystal Biotech from $201.00 to $206.00 and gave the company an "outperform" rating in a report on Monday, August 12th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $197.00.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now directly owns 1,500,882 shares in the company, valued at $296,814,424.32. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 14.10% of the stock is owned by corporate insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).